Core Viewpoint - The company emphasizes that its stock price is influenced by various factors including macroeconomic environment, policy landscape, industry cycles, and operational performance, leading to a relatively stable stock price recently [1] Group 1: Strategic Initiatives - The company is accelerating its strategic transformation and upgrading efforts while continuously strengthening its core competitiveness [1] - The CDMO (Contract Development and Manufacturing Organization) business is experiencing sustained growth and has become the highest gross margin segment for the company, serving as a major driver for performance improvement [1] Group 2: Shareholder Returns - The company places significant importance on shareholder returns, consistently implementing cash dividends and share buybacks to enhance shareholder value [1] - The company aims to genuinely allow investors to share in the growth and success of the company [1]

Group 1 - The company acknowledges that its stock price is influenced by various factors including macroeconomic environment, policy landscape, industry cycles, and operational performance [1] - The company emphasizes its commitment to value creation and sharing, highlighting its strategic transformation and enhancement of core competitiveness [1] - The CDMO business segment is noted as the highest gross margin area and a key driver of the company's performance growth [1] Group 2 - The company is focused on enhancing shareholder returns through cash dividends and share buybacks [1] - The management expresses gratitude for investor attention and aims to ensure that investors share in the company's development achievements [1]

证券日报网讯1月9日，亿帆医药（002019）发布公告称，公司及控股子公司未对合并报表范围外的单位 提供担保，也无逾期担保累计金额、涉及诉讼的担保金额及因担保被判决败诉而应承担的损失金额。 ...

海思科公告称，公司2020年非公开发行股票募集资金净额7.91亿元，募投项目已整体结项。公司拟 将"盐酸乙酰左卡尼汀片的中国上市后再评价项目"节余募集资金1641.52万元永久补充流动资金；"长效 口服降血糖新药HSK - 7653项目"部分节余5301.75万元用于"新型外周神经痛治疗药物HSK16149胶囊项 目"。截至2025年12月31日，募集资金专户余额2.26亿元。为提高资金使用效率，公司拟自2026年2月10 日起12个月内，使用不超2.3亿元闲置募集资金进行现金管理，资金可循环滚动使用。该事项已获董事 会等审议通过，保荐机构无异议。 ...

海南海药公告称，持股5.26%的股东云南国际信托有限公司－聚利36号单一资金信托，因自身资金需 求，计划在公告披露之日起15个交易日后的连续90个自然日内，以集中竞价交易方式减持不超 12,973,651股，占公司总股本的1%。股份来源为要约收购所得。本次减持计划实施存在不确定性，且不 会导致公司控制权变更及对持续经营产生重大影响。 ...

公告显示，依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉内血栓形成)，特别是与骨科或普 外手术有关的血栓形成;治疗已形成的深静脉栓塞，伴或不伴有肺栓塞，临床症状不严重，不包括需要 外科手术或溶栓剂治疗的肺栓塞;与阿司匹林合用，治疗不稳定性心绞痛及非Q波心肌梗死;用于血液透 析体外循环中，防止血栓形成。 智通财经APP讯，常山药业(300255.SZ)公告，公司药品依诺肝素钠注射液在美国的新药简略申请(简称 ANDA，即美国仿制药申请)获得美国食品药品监督管理局(简称美国FDA)的批准。 ...

常山药业（300255）(300255.SZ)公告，公司药品依诺肝素钠注射液在美国的新药简略申请(简称 ANDA，即美国仿制药申请)获得美国食品药品监督管理局(简称美国FDA)的批准。 公告显示，依诺肝素钠注射液用于预防静脉血栓栓塞性疾病(预防静脉内血栓形成)，特别是与骨科或普 外手术有关的血栓形成;治疗已形成的深静脉栓塞，伴或不伴有肺栓塞，临床症状不严重，不包括需要 外科手术或溶栓剂治疗的肺栓塞;与阿司匹林合用，治疗不稳定性心绞痛及非Q波心肌梗死;用于血液透 析体外循环中，防止血栓形成。 ...

Core Viewpoint - Jiuzhou Pharmaceutical announced that its wholly-owned subsidiary, Zhejiang Ruibo Pharmaceutical Co., Ltd., has been recognized as a high-tech enterprise, which may enhance its competitive position and innovation capabilities in the pharmaceutical industry [2]. Group 1 - The announcement was made on January 9, indicating the company's proactive approach to innovation and technology [2]. - The certification was issued by the National High-tech Enterprise Recognition Management Work Leading Group Office, highlighting the credibility of the recognition process [2]. - The certificate number is GR202533010708, with an issuance date of December 19, 2025, and a validity period of three years [2].

Core Viewpoint - The company has received acceptance from the National Medical Products Administration for the clinical trial application of its innovative drug SAL0150, aimed at treating type 2 diabetes and its complications, as well as obesity or overweight conditions [1] Group 1: Drug Development - SAL0150 is an oral long-acting medication with independent intellectual property rights, expected to allow for administration once a week or longer [1] - If successfully developed and approved for market, SAL0150 could enhance the company's pipeline of innovative products in the chronic disease sector [1] Group 2: Market Impact - The drug development cycle is lengthy and carries high risks, with uncertainties from clinical trials to market approval [1] - There is no immediate impact on the company's performance in the short term due to the nature of drug development [1]

广济药业公告称，于2026年1月9日召开董事会会议，同意对全资子公司生物研究院减少注册资本2200万 元。减资前，生物研究院注册资本为5000万元，减资后将减至2800万元，公司仍持股100%，不影响合 并报表范围。生物研究院2025年1 - 9月营收235.85万元、净利润 - 131.02万元，2024年营收59.91万元、 净利润 - 576.12万元。本次减资是基于战略规划，利于优化资产结构，提升管理效率，不会对当期损益 造成重大影响。 ...